沈建華

2000年中科院上海藥物所博士后流動站出站后留所工作，從事新葯設計研究工作。

研究方向

目前主要從事糖尿病與心血管新葯藥學研究，具體課題包括：抗糖尿病和抗動脈粥樣硬化症天然活性化合物的結構優化；基於靶標結構的抗代謝綜合症藥物先導化合物的設計與合成；治療多囊腎藥物先導化合物的臨床前研究；中藥復方的深度開發。

科研項目

承擔了自然科學基金項目、科技部生物和信息領域 863 項目、 973 計劃 SARS 防治專項、上海市基礎重點研究項目等。

代表論著

1. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.Invest New Drugs.

2. Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors. Eur J Med Chem. 2009 Mar;

3. Design, synthesis and biological evaluation and molecular modelingof α-Aryloxy-α-methylhydrocinnamic Acids as PPARγ agonists and 11β-HSD1 inhibitors with antihyperglycemia and lipid modulating activity. Bioorg Med Chem

4. (Phenylsulfonamidomethyl)benzamides as Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type1 with Efficacy in diabetic ob/ob mice. Bioorg Med Chem

5. 4-(Phenylsulfonamidomethyl)benzamides as Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1 with Efficacy in diabetic ob/ob mice. Acta Pharmacol Sin

6. Discovery of novel inhibitors of 11b-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. Bioorganic & Medicinal Chemistry Letters

7. Conformational transition of amyloid beta –peptide.PNAS

8. How Does Huperzine A Enter and Exit the Active Site of Acetylcholinesterase? Steered Molecular Dynamics Simulations. J. Am. Chem. Soc

9. Virtual Screening on Natural Products for Discovering Active Compounds and Target Clues. Curr. Med. Chem

10. Steered Molecular Dynamics Simulation on the Binding of NNRTI to HIV-1 RT. Biophys. J.